Insmed Incorporated (NASDAQ:INSM) Insider Sells $1,006,625.12 in Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 13,436 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the sale, the insider now directly owns 106,134 shares in the company, valued at $7,951,559.28. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Insmed Price Performance

Shares of NASDAQ:INSM traded down $1.43 during midday trading on Monday, hitting $73.23. The stock had a trading volume of 1,402,956 shares, compared to its average volume of 2,436,028. The company’s 50-day moving average price is $74.65 and its 200-day moving average price is $50.60. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $80.53. The company has a quick ratio of 2.53, a current ratio of 2.71 and a debt-to-equity ratio of 25.05. The company has a market capitalization of $10.88 billion, a P/E ratio of -14.28 and a beta of 1.11.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The business had revenue of $90.34 million for the quarter, compared to analyst estimates of $87.95 million. Insmed’s quarterly revenue was up 17.0% on a year-over-year basis. During the same period in the prior year, the company posted ($1.78) EPS. As a group, equities research analysts predict that Insmed Incorporated will post -5.42 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. UBS Group boosted their price target on Insmed from $78.00 to $84.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Barclays boosted their target price on Insmed from $40.00 to $63.00 and gave the stock an “overweight” rating in a report on Wednesday, May 29th. Stifel Nicolaus raised their price target on Insmed from $74.00 to $88.00 and gave the company a “buy” rating in a report on Friday, August 9th. TD Cowen upped their price objective on shares of Insmed from $75.00 to $98.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, Guggenheim raised their target price on shares of Insmed from $70.00 to $95.00 and gave the stock a “buy” rating in a research note on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $79.19.

Institutional Trading of Insmed

Several institutional investors and hedge funds have recently modified their holdings of the business. Victory Capital Management Inc. grew its position in Insmed by 21.4% in the fourth quarter. Victory Capital Management Inc. now owns 18,797 shares of the biopharmaceutical company’s stock valued at $583,000 after acquiring an additional 3,311 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Insmed by 2.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,128,436 shares of the biopharmaceutical company’s stock valued at $34,970,000 after purchasing an additional 28,629 shares in the last quarter. QRG Capital Management Inc. bought a new stake in shares of Insmed during the 4th quarter valued at approximately $246,000. Norges Bank bought a new stake in shares of Insmed during the 4th quarter valued at approximately $45,029,000. Finally, UBS Group AG increased its position in Insmed by 145.6% during the 4th quarter. UBS Group AG now owns 300,181 shares of the biopharmaceutical company’s stock worth $9,303,000 after purchasing an additional 177,981 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.